T h e W o r k : P rofessional A dvertising Important Safety Information LUNESTA, like other hypnotics, has CNS-depressant effects. Because of the rapid onset of action, LUNESTA should only be ingested immediately prior to going to bed or after the patient has gone to bed and has experienced difficulty falling asleep. Patients should not take LUNESTA unless they are prepared to get a full night’s sleep. As with other hypnotics, patients receiving LUNESTA should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination (eg, operating machinery or driving a motor vehicle) after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of LUNESTA. In clinical trials, the most common adverse events associated with LUNESTA were unpleasant taste, headache, somnolence, dizziness, dry mouth, infection, and pain. LUNESTA has been classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation.The risk of abuse and dependence increases with the dose and duration of treatment and concomitant use of other psychoactive drugs. The risk is also greater for patients who have a history of alcohol or drug abuse or history of psydiiatric disorders. These patients should be under careful surveillance when receiving LUNESTA or any other hypnotic. Sedative/hypnotic drugs should be administered with caution to patients exhibiting signs and symptoms of depression. Suicidal tendencies may be present in such patients, and protective measures may be required. Intentional overdose is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time. MtitiKTf. I.lyytfjj/WKtftnXlMtaMto Su-ihnvqiWV,o'*vc$idw*owrI d rxgNfrfcolntnt rouftr* j r* r.*xnr.*e<* teatnxSUIP JCttUt'. W .’[n 2. Jj'WiMlCK. MrNatOl. tow J. a MMcicy .«•*!-.iWi c» xjva p tor wmtm ../rUvrtoifcit 20 I W W I 1 UHESMrnsMtxwj nkrnwton For refreshing sleep— night after night after night • First and only hypnotic agent approved for long-term use • First and only non-benzodiazepine with an FDA-approved indication for sleep maintenance • No evidence of tolerance—even after 6 months of use’ • No significant rebouncJ insomnia at doses up to 3 mg and no next-day residual effects in most patients7-3 • The failure of insomnia to remit after 7 to 10 days of treatment should be medically evaluated Leave the rest to... NEW 1,2 AND 3 MG TABLETS Stf’RACOR '.'.A.y.'stiWiCOfiI'M. mamwskr i. vaoi w it , 4$n/oui, Pleasu sot* brief summary of complete proscribing informjtion. 1. AGENCY: Lehman Millett CREATIVE TEAM: Deborah Lotterman, Bob Schiffrar, Eric Levreault, Jim Huibregtse CLIENT: SONY 2. AGENCY: echo Torre Lazur CREATIVE TEAM: Jennifer Rodriguez, Juan Ramos, Tracy Blackwell CLIENT: Sepracor 203
RkJQdWJsaXNoZXIy NDMwNDAx